PEP/NEWS — Peptide intel. Daily.

Join Thrive Market today and get $20 off your first three orders plus a free $60 gift! http://thrivemarket.com/Thomas This video does contain a paid partnership with a brand that helps to support this channel. It is because of brands like

🎯 Dr. Durst sits down with integrative oncologist and breast surgeon Dr. Jen Simmons @dr.jennsimmons for one of the most eye-opening conversations you'll hear about breast cancer — from a doctor who lived it herself. Dr. Simmons grew up wa

Part one of a three-part deep dive maps the cellular pathways that cancer hijacks — many of which overlap with the same signaling cascades that peptide researchers study for healing and recovery. A necessary foundation for anyone tracking the peptide-oncology intersection.

Reviewers in Aging Cell mapped the relationship between cellular senescence, vascular overgrowth, and tumor formation. The findings strengthen the case for senolytics as a cancer-adjacent research priority.

Bryan Johnson's cardiovascular stack has produced blood pressure scores lower than 90% of 18-year-olds. He breaks down four protocols driving his results — a useful editorial reference for understanding what aggressive cardiovascular optimization looks like in practice.

Anodyne Nanotech closed a $12.6 million Series A to move its once-weekly GLP-1 patch into Phase 1 trials. If transdermal delivery works at therapeutic levels, it could meaningfully expand access to GLP-1 therapy beyond injectable formats.

Muscle-targeted delivery of FGF21 (a metabolic signaling protein) extended median lifespan in male mice by 20% and improved multiple healthspan markers. The findings add weight to metabolic signaling as a lever for late-life intervention.

Fight Aging! compiled a list of interventions with published evidence for reducing epigenetic age in humans. For researchers tracking biological aging endpoints, this is a useful reference snapshot of where the evidence currently stands.

NeuroAge Therapeutics announced Younger 2027, a six-month competition measured on a clinical-grade aging panel. The contest format is unconventional, but the underlying biomarker infrastructure is real — and may generate useful longitudinal data.

Attia unpacks why high HDL-C may not be protective in the way most people assume. The piece challenges a core piece of conventional cardiovascular dogma with current epidemiological and mechanistic data.

Scribe secured $25 million to advance two one-time CRISPR treatments for inherited cardiovascular risk toward human trials. One-time genetic correction as an alternative to lifelong medication is gaining serious funding momentum.

UniXell secured IND clearance from both the FDA and China's NMPA for a stem cell-derived dopaminergic therapy for Parkinson's. Dual regulatory green lights in major markets simultaneously is a notable milestone.